During the past decade, Universitätsklinikum Essen, Klinik für Hämatologie conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 1 clinical trials were completed, i.e. on average, 10% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Essen, Klinik für Hämatologie" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "University of Heidelberg Medical Center" with 2 trials sponsored, "Celgene Corporation" with 1 trials sponsored, "Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH" with 1 trials sponsored and "International Extranodal Lymphoma Study Group (IELSG)" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Essen, Klinik für Hämatologie" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator and "Celgene Corporation" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Essen, Klinik für Hämatologie" are "Multiple Myeloma" (2 trials), "Myelodysplastic Syndromes" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Acute Myeloid Leukemia in Remission" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "Universitätsklinikum Essen, Klinik für Hämatologie" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Essen, Klinik für Hämatologie" are "Drug" (15 trials), "Device" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (3 trials), "Dexamethasone" (3 trials), "Lenalidomide" (3 trials), "Rituximab" (3 trials) and "Venetoclax" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Essen, Klinik für Hämatologie" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Essen, Klinik für Hämatologie". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Universitätsklinikum Essen, Klinik für Hämatologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Essen, Klinik für Hämatologie, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".